There is an allegation that a HIV drug known as abacavir can trigger heart attack. But now, there was nothing to worry about, because research has confirmed that the HIV drug Abacavir does not trigger heart attack.
Abacavir is an ingredient in HIV drug Epzicom, Trizivir and Ziagen that produced and sold by ViiV Healthcare, a unit of joint venture between Pfizer Inc. and GlaxoSmithKline Plc. Glaxo is the majority partner.
In recent reports, Food and Drug Administration (FDA) has confirm, an abacavir is safe as other HIV drugs and not shown to increase the risk of heart attack.
This research result is published after the FDA browse 26 clinical trials report that analyze the link between abacavir and heart attack risk. HIV-infected patients or doctors now do not need to worry about using the HIV drugs with an active ingredient abacavir
